DarioHealth
DarioHealth's revenue fell 17.3% to $22 million in fiscal 2025. Its operating margin was −163.9%, up from −213.6% a year earlier. Free cash flow was −$26 million. The diluted share count rose 62.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
DarioHealth lost money in fiscal 2025: a net loss of $42 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 36 | 49 | 37 | 28 | 22 |
| Debt incl. finance leases | 0 | 27 | 28 | 29 | — |
| Net debt (negative means net cash) | −36 | −22 | −8 | 1 | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.3x | 0.5x | 0.4x | — |
| Interest coverage | — | −30.3x | −13.9x | −14.7x | −12.1x |
| Current ratio | 3.2x | 3.4x | 3.8x | 2.4x | 3.8x |
| Quick ratio | 2.7x | 3.0x | 3.4x | 2.1x | 3.3x |
Cash flow
Projections
Project DarioHealth's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $100,000 of DarioHealth shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 23, 2026 | Dennis MatheisDirector | Bought | 14,430 | $6.93 | $100,000 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 4 of 9 | — |
| Rule of 40 | −178.6% | −110.3% | −134.0% |
| Altman Z'' | −11.77 | −11.04 | −12.40 |
| Accruals ratio | −26.9% | −3.9% | −13.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | 3 of 9 | 4 of 9 | — |
Compare
Put DarioHealth side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| DarioHealth | FY25 | −17.3% | −163.9% | −116.7% | — | — | — | |
| Baird Medical Investment | FY25 | −39.1% | −113.7% | −6.2% | −50.0% | — | 1 | Compare |
| Lifeward | FY25 | −14.1% | −89.3% | −76.4% | — | — | — | Compare |
| Jin Medical International | FY25 | −12.0% | 2.9% | −18.0% | — | — | — | Compare |
| Spectral AI | FY25 | −33.6% | −43.8% | — | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 3 | 5 | 7 | 8 | 8 | 20 | 28 | 20 | 27 | 22 |
| Revenue growth | 240.6% | 84.5% | 43.0% | 2.2% | 0.2% | 170.8% | 34.8% | −26.4% | 32.9% | −17.3% |
| Gross profit | −1 | 1 | 2 | 3 | 2 | 4 | 10 | 6 | 13 | 13 |
| Research and development | 2 | 3 | 4 | 4 | 4 | 17 | 20 | 20 | 24 | 14 |
| Operating income | −11 | −14 | −18 | −18 | −30 | −76 | −57 | −56 | −58 | −37 |
| Net income | −11 | −16 | −18 | −18 | −29 | −77 | −62 | −59 | −43 | −42 |
| Diluted EPS (US$) | — | — | — | — | 80.20 | — | — | — | 12.27 | — |
| Diluted shares (millions) | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 4 |
| Cash flow | ||||||||||
| Cash from operations | −8 | −11 | −12 | −16 | −18 | −50 | −48 | −30 | −39 | −26 |
| Capital expenditure | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Free cash flow | −9 | −11 | −12 | −16 | −18 | −51 | −48 | −31 | −39 | −26 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 0 |
| Stock-based compensation | 1 | 4 | 4 | 2 | 11 | 25 | 17 | 20 | 0 | 9 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 1 | 4 | — | 20 | 29 | 36 | 49 | 37 | 28 | 22 |
| Debt incl. finance leases | — | — | — | — | — | 0 | 27 | 28 | 29 | — |
| Total assets | 4 | 7 | 14 | 25 | 35 | 101 | 119 | 96 | 119 | 110 |
| Total liabilities | 10 | 3 | 5 | 6 | 7 | 15 | 39 | 38 | 47 | 42 |
| Shareholders' equity | −6 | 4 | 9 | 19 | 28 | 86 | 80 | 58 | 72 | 68 |
| Margins and ratios | ||||||||||
| Gross margin | −29.6% | 25.4% | 23.9% | 34.4% | 33.2% | 19.3% | 34.9% | 29.4% | 49.1% | 56.6% |
| Operating margin | −396.0% | −278.9% | −239.2% | −234.2% | −394.7% | −372.9% | −205.4% | −276.1% | −213.6% | −163.9% |
| Net margin | −388.4% | −304.5% | −240.8% | −234.6% | −388.7% | −374.2% | −224.9% | −292.0% | −158.1% | −186.6% |
| Free cash flow margin | −327.8% | −209.2% | −156.1% | −209.3% | −235.7% | −247.0% | −174.6% | −152.1% | −143.1% | −116.7% |
| Rule of 40 (growth + FCF margin) | −87.2% | −124.7% | −113.1% | −207.1% | −235.4% | −76.2% | −139.8% | −178.6% | −110.3% | −134.0% |
| Return on capital | — | — | — | — | — | — | −83.6% | −82.6% | −74.1% | — |
| Return on equity | — | — | −276.7% | −127.5% | −125.2% | −135.0% | −75.1% | −86.0% | −65.7% | −59.6% |
| Return on assets | −243.3% | −290.8% | −169.2% | −91.8% | −98.2% | −112.7% | −56.5% | −55.1% | −39.7% | −36.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |